BUSINESS

Mitsubishi Tanabe Eyes US as 1st Launch Market, Zeroes in on Immunology/CNS: Chief

January 22, 2019
Mitsubishi Tanabe Pharma is poised to place the highest priority on its business in the US, looking to make it its first launch market even ahead of Japan, with a laser focus on autoimmune diseases/inflammation and CNS, President Masayuki Mitsuka…

To read the full story

Related Article

BUSINESS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…